Post-dilatation of an interwoven nitinol stent using a paclitaxel-coated balloon for revascularization of complex femoro-popliteal lesions.
Angioplasty
Femoral artery
Paclitaxel
Popliteal artery
Self expandable metallic stents
Journal
Cardiovascular intervention and therapeutics
ISSN: 1868-4297
Titre abrégé: Cardiovasc Interv Ther
Pays: Japan
ID NLM: 101522043
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
20
05
2020
accepted:
06
08
2020
pubmed:
18
8
2020
medline:
20
7
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
To evaluate technical success, safety and efficacy of post-dilatation of an interwoven nitinol stent using a paclitaxel-coated balloon (PCB) for revascularization of complex femoro-popliteal lesions. Thirty patients (26 male, mean age 70 ± 7 years) suffering from peripheral artery disease (PAD) (Rutherford category II-III) underwent revascularization of chronic total occlusions (n = 22, 73%) or severe stenosis (n = 8, 27%) of the femoro-popliteal segment. Mean lesion length was 251 ± 85 mm. Lesions were treated by pre-dilatation (POBA), implantation of a helical interwoven stent and post-dilatation with a PCB. Technical success was defined as residual stenosis < 30%. Follow-up included clinical visits, duplex ultrasound and ABI at 6 and 12 months. Endpoints were patency (re-stenosis < 50%), complications, improvement of Rutherford category and ABI. Regarding patency two sub-groups were compared: long-("LL"; < 25 cm, n = 12, mean 175 ± 38 mm) and ultra-long lesions ("ULL"; ≥ 25 cm, n = 13, mean 322 ± 43 mm). Technical success was 100%. In 1/30 patients (3.3%), a minor complication occurred (embolism). The overall primary and secondary patency rates at 12 months were 80.0% (95% CI 72.5-96.9%) and 92.0% (95% CI 84.7-100%). In the LL-sub-group, primary patency was 100%, and in the ULL-sub-group, primary patency was 61.5% (95% CI 51.8-92.3%) (p = 0.056), and secondary patency 84.6% (95% CI 71.3-100%), respectively. Rutherford category increased by at least one category in 92% of patients, ABI increased from 0.52 ± 0.13 (baseline) to 0.9 ± 0.14 (12 months) (p = 0.001). Five patients underwent target lesion revascularization during follow-up (bypass: n = 1, endovascular: n = 4). No death was observed during follow-up. Post-dilatation of an interwoven nitinol stent using a paclitaxel-coated-balloon proved to be safe and effective with promising outcomes in long- and ultra-long lesions up to 12 months of follow-up.
Identifiants
pubmed: 32803671
doi: 10.1007/s12928-020-00697-9
pii: 10.1007/s12928-020-00697-9
doi:
Substances chimiques
Alloys
0
nitinol
2EWL73IJ7F
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
338-346Références
Hardman RL, Jazaeri O, Yi J, Smith M, Gupta R. Overview of classification systems in peripheral artery disease. Semin Interv Radiol. 2014;31:378–88.
doi: 10.1055/s-0034-1393976
Davaine JM, Azema L, Guyomarch B, Chaillou P, Costargent A, Patra P, et al. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA “STEnting Long de L’Artere femorale superficielle” cohort). Eur J Vasc Endovasc Surg. 2012;44:432–41.
doi: 10.1016/j.ejvs.2012.07.015
Joo HJ, Jang DH, Yu CW, Choi YJ, Park J, Lee HJ, et al. Efficacy and safety of endovascular treatment for femoropopliteal lesions of TASC II type C and D compared with TASC II type A and B in Korea. Vascular. 2017;25:351–8.
doi: 10.1177/1708538116678539
Rabellino M, Zander T, Baldi S, Garcia Nielsen L, Aragon-Sanchez FJ, Zerolo I, et al. Clinical follow-up in endovascular treatment for TASC C-D lesions in femoro-popliteal segment. Catheter Cardiovasc Interv. 2009;73:701–5.
doi: 10.1002/ccd.21971
Lawall H, Huppert P, Espinola-Klein C, Zemmrich CS, Ruemenapf G. German guideline on the diagnosis and treatment of peripheral artery disease—a comprehensive update 2016. VASA. 2017;46:79–86.
doi: 10.1024/0301-1526/a000603
Brouillet J, Deloose K, Goueffic Y, Poirier M, Midy D, Caradu C, Ducasse E, et al. Primary stenting for TASC C and D femoropopliteal lesions: one-year results from a multicentric trial on 203 patients. J Cardiovasc Surg (Torino). 2018;59:392–404.
Shammas NW, Coiner D, Shammas G, Jerin M. Predictors of provisional stenting in patients undergoing lower extremity arterial interventions. Int J Angiol. 2011;20:95–100.
doi: 10.1055/s-0031-1279683
Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83:212–20.
doi: 10.1002/ccd.25387
Muller-Hulsbeck S, Keirse K, Zeller T, Schroe H, Diaz-Cartelle J. Twelve-month results from the MAJESTIC trial of the eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease. J Endovasc Ther. 2016;23:701–7.
doi: 10.1177/1526602816650206
Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–53.
doi: 10.1056/NEJMoa1406235
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–10.
doi: 10.1583/05-1704.1
Bosiers M, Peeters P, Tessarek J, Deloose K, Streckler S. The Zilver(R) PTX(R) Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino). 2013;54:115–22.
Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–38.
doi: 10.1016/j.jacc.2015.09.063
de Boer SW, van den Heuvel DAF, de Vries-Werson DAB, Vos JA, Fioole B, Vroegindeweij D, et al. Short-term results of the RAPID randomized trial of the Legflow paclitaxel-eluting balloon with supera stenting vs supera stenting alone for the treatment of intermediate and long superficial femoral artery lesions. J Endovasc Ther. 2017;24:783–92.
doi: 10.1177/1526602817725062
Garcia LA, Rosenfield KR, Metzger CD, Zidar F, Pershad A, Popma JJ, et al. SUPERB final 3-year outcomes using interwoven nitinol biomimetic supera stent. Catheter Cardiovasc Interv. 2017;89:1259–67.
doi: 10.1002/ccd.27058
Bhatt H, Kovach R, Janzer S, George JC. SUPERA stent outcomes in Above-The-Knee IntervEntions: effects of COMPression and ELongation (SAKE-COMPEL) Sub-study. Cardiovasc Revasc Med. 2018;19:512–5.
doi: 10.1016/j.carrev.2017.11.007
Mwipatayi BP, Perera K, Daneshmand A, Daniel R, Wong J, Thomas SD, et al. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease. Vascular. 2018;26:3–11.
doi: 10.1177/1708538117705805
Tacke J, Muller-Hulsbeck S, Schroder H, Lammer J, Schurmann K, Gross-Fengels W, et al. The randomized freeway stent study: drug-eluting balloons outperform standard balloon angioplasty for postdilatation of nitinol stents in the SFA and PI segment. Cardiovasc Interv Radiol. 2019;42:1513–21.
doi: 10.1007/s00270-019-02309-3
Bosiers M. DCB + stent in the SFA: 12-month results of the Biolux4ever trial. Presentation at LINC 2017, Leipzig, Germany, 24–27 January 2017.
Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102–8.
doi: 10.1016/j.jcin.2014.07.023
Micari A, Brodmann M, Keirse PP, Tepe G, Frost M, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT global study. JACC Cardiovasc Interv. 2018;11:945–53.
doi: 10.1016/j.jcin.2018.02.019
Iida O, Takahara M, Mano T. What does the IN.PACT SFA-long study tell us? JACC Cardiovasc Interv. 2017;10:735–7.
doi: 10.1016/j.jcin.2017.03.005
Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.
doi: 10.1161/CIRCULATIONAHA.114.011004
Schmidt A, Piorkowski M, Gorner H, Steiner S, Brausback Y, Scheinert S, et al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715–24.
doi: 10.1016/j.jcin.2015.12.267
Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417–27.
doi: 10.1016/j.jacc.2013.03.034
George JC, Rosen ES, Nachtigall J, VanHise A, Kovach R. SUPERA interwoven nitinol stent outcomes in Above-Knee IntErventions (SAKE) study. J Vasc Interv Radiol. 2014;25:954–61.
doi: 10.1016/j.jvir.2014.03.004
Garcia L, Jaff MR, Metzger C, et al. Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries: twelve-month results of the SUPERB trial. Circ Cardiovasc Interv. 2015;8:e000937.
doi: 10.1161/CIRCINTERVENTIONS.113.000937
Scheinert D, Werner M, Scheinert S, Paetzold A, Banning-Eichenseer U, Piorkowski M, et al. Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent: 12-month results of the Leipzig SUPERA popliteal artery stent registry. JACC Cardiovasc Interv. 2013;6:65–71.
doi: 10.1016/j.jcin.2012.09.011
Myint M, Schouten O, Bourke V, Thomas SD, Lennox AF, Varcoe RL. A real-world experience with the supera interwoven nitinol stent in femoropopliteal arteries: midterm patency results and failure analysis. J Endovasc Ther. 2016;23:433–41.
doi: 10.1177/1526602816639543
Montero-Baker M, Ziomek GJ, Leon L, Gonzales A, Dieter RS, Gadd CL, et al. Analysis of endovascular therapy for femoropopliteal disease with the supera stent. J Vasc Surg. 2016;64:1002–8.
doi: 10.1016/j.jvs.2016.04.053
Palena LM, Diaz-Sandoval LJ, Sultato E, Brigato C, Candeo A, Brocco E, et al. Feasibility and 1-year outcomes of subintimal revascularization with supera((R)) stenting of long femoropopliteal occlusions in critical limb ischemia: The "Supersub" Study. Catheter Cardiovasc Interv. 2017;89:910–20.
doi: 10.1002/ccd.26863
Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
doi: 10.1161/JAHA.118.011245